Condition: Unresectable Breast Cancer · Metastatic Breast Cancer · HER2-low Expressing Breast Cancer · Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.
This description comes directly from the study's public registry record.
Contact for Clinical Trial Information · 908-992-6400 · CTRinfo@dsi.com
Always discuss trial participation with your own doctor first.
| Medizinische Universität Graz | Graz, Austria | Terminated |
| Medizinische Universität Graz | Graz, Austria | Recruiting |
| Medizinische Universität Innsbruck | Innsbruck, Austria | Recruiting |
| Klinikum Klagenfurt am Wörthersee | Klagenfurt, Austria | Recruiting |
| LKH Hochsteiermark-Leoben | Leoben, Austria | Withdrawn |
| Ordensklinikum Linz GmbH Barmherzige Schwestern | Linz, Austria | Recruiting |
| Interne II, LKH Feldkirch | Rankweil, Austria | Active Not Recruiting |
| KH der Barmherzigen Brüder Salzburg | Salzburg, Austria | Recruiting |
| Uniklinikum Salzburg | Salzburg, Austria | Recruiting |
| Medical University of Vienna | Vienna, Austria | Recruiting |
| Medizinische Universität Wien | Vienna, Austria | Terminated |
| Krankenhaus Hietzing | Vienna, Austria | Recruiting |
+ 199 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05945732